IMCR - Immunocore doses first patient in IMC-I109V chronic hepatitis B trial

Immunocore Holdings (IMCR) announces the dosing of the first patient in the first-in-human clinical trial of IMC-I109V, a new class of bispecific protein immunotherapy that is being developed for the treatment of patients with chronic hepatitis B ((HBV)) infection ((CHB)).The trial is an open label study evaluating the safety, antiviral activity, and pharmacokinetics of IMC-I190V in certain patients with chronic HBV who are non-cirrhotic, hepatitis B antigen-negative, and virally suppressed.IMC-I109V is an immunotherapeutic approach designed to potentially eliminate HBV-infected hepatocytes expressing hepatitis B surface antigen ((HBsAg)) via T cell redirection.

For further details see:

Immunocore doses first patient in IMC-I109V chronic hepatitis B trial